Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 84
3 119
2 31
1 18
Curative setting
A 34
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 43
Genitourinary Cancers 49
Gynaecological Malignancies 28
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 20
Thoracic Malignancies 64
Curative setting
Breast Cancer 6
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 2
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
Thoracic Malignancies 2

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
FOLFIRINOX - Gemcitabine 1st line advanced or metastatic. Good performance status Gastrointestinal Cancers Pancreatic cancer - Metastatic
5
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% Metastatic
5
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% Metastatic
5
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC >50% tumour cell PD-L1 expression Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥50% Metastatic
5
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>50% tumour cell PD-L1 expression Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥50% Metastatic
5
Nivolumab - Docetaxel 2nd line after platinum-based therapy advanced squamous-cell NSCLC Thoracic Malignancies Non-small-cell Lung Cancer - Squamous cell - Metastatic
5
Nivolumab - Docetaxel 2nd line after platinum-based therapy advanced non-squamous-cell NSCLC stratified for PD-L1 Thoracic Malignancies Non-small-cell Lung Cancer - Metastatic
5
Pembrolizumab - Platinum-based chemotherapy 1st line metastatic and advanced NSCLC with PD-L1>50% Thoracic Malignancies Non-small-cell Lung Cancer - Metastatic and advanced
5
Dab/Tram (dabrafenib and trametinib) - Vemurafenib 1st line unresectable or metastatic melanoma with the BRAF V600E mutation Skin Cancers Melanoma BRAF V600E Metastatic
5
Radium-223 Best standard of care Best standard of care + placebo Late line and bone pain, castration-refractory, late line and bone pain Genitourinary Cancers Prostate cancer - Metastatic
5

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.